On September 28, 2024 Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, reported the presentation of new data at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place September 29 – October 2, 2024, in Washington, D.C. (Press release, Naveris, SEP 28, 2024, View Source [SID1234646911]). These presentations will showcase the role of the NavDx test, the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test, in the management of HPV-driven oropharyngeal cancers, with a focus on integration into radiation oncology practices.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ASTRO is the premier gathering for radiation oncology professionals, providing the perfect platform to showcase how the NavDx test is transforming the care of patients with HPV-driven cancers," said Barry M. Berger, M.D., Chief Medical Officer at Naveris. "These presentations will highlight the role of testing in personalizing treatment, enhancing real-time surveillance, and ultimately improving patient outcomes in the field of radiation oncology."
Oral Presentations:
The following presentation will be part of SS 37 – H&N 1: Envisioning the Future: Leading Edge Research in HPV-Associated Oropharyngeal Cancer on Tuesday, October 1, 2024, from 3:00 PM – 4:00 PM EDT at the Walter E. Washington Convention Center (WWCC), Room 145:
Tuesday, October 1, 2024 | 4:40 PM – 4:50 PM EDT
The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma
Presenting Author: Li Wang, M.D., Ph.D. | Senior Author: Steven Frank, M.D.
MD Anderson Cancer Center, Houston, TX
This large study analyzed over 1,000 blood samples and showed that the NavDx test can identify patients at risk for treatment failure earlier than imaging, demonstrating its potential as a robust biomarker to guide treatment intensity in HPV+ OPSCC.
The following educational session presentation will also incorporate a discussion of the NavDx test:
Monday, September 30, 2024 | 10:30 AM – 11:30 AM EDT | Room 151
EDU 24 – Integration of HPV ctDNA Testing into Clinical Practice for HPV+ OPSCC – Ready for Prime Time?
Moderator: John Lukens, M.D. | Speakers: David Routman, M.D., Michelle Mierzwa, M.D., Dan Faden, M.D.
University of Pennsylvania, Mayo Clinic, University of Michigan, Mass General Brigham
This educational session will explore the use of HPV ctDNA testing in clinical practice for HPV+ OPSCC, incorporating the NavDx test as part of a broader discussion on using ctDNA for treatment guidance and monitoring.
Poster Presentations:
The following posters will be part of PQA 10 – Head & Neck Cancer and Health Services Research/Global Oncology on Wednesday, October 2, 2024, from 10:30 AM – 11:45 AM EDT at WWCC, Hall C:
(3608) The Impact of Circulating Tumor Human Papillomavirus (HPV) DNA Clearance Kinetics on Disease Outcomes during Chemoradiation in Patients with HPV-Associated Oropharyngeal Cancer
Presenter: Sujith Baliga, M.D. | Senior Author: David M. Blakaj, M.D., Ph.D.
The Ohio State University, Columbus, OH
This study shows that changes in NavDx test results during treatment can predict outcomes, with rapid clearance indicating better control and persistent positivity suggesting higher risk, highlighting NavDx as a tool for adjusting radiation therapy intensity based on patient risk.
(3718) Tracking Circulating Tumor HPV DNA with Early Cessation of Radiotherapy in Oropharynx Cancer
Presenter: Zubir Rentiya, M.D., MSc | Senior Author: Charles McLaughlin, M.D.
University of Virginia, Charlottesville, VA
This study shows that using mid-treatment NavDx test results to guide early cessation of radiotherapy led to excellent outcomes, with superior progression-free survival compared to patients completing the full course of treatment.
(3639) Comparative Performance of ctHPVDNA and Imaging Surveillance for Oropharyngeal Cancer Following Radiotherapy
Presenter: Yifu Ding, M.D., Ph.D. | Senior Author: Walter A. Stokes, M.D.
Winship Cancer Institute of Emory University, Atlanta, GA
This study found that NavDx outperforms imaging in post-radiotherapy surveillance, with fewer false positives and higher specificity.
Naveris will be exhibiting at the conference at Booth #2037, where attendees can learn more about NavDx and its impact on improving care for patients with HPV-driven cancers in radiation oncology.
For more information about Naveris and NavDx, please visit www.naveris.com and www.NavDx.com.